A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2018
At a glance
- Drugs Nivolumab (Primary) ; TG 4010 (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Transgene
- 21 Sep 2018 Planned End Date changed from 1 May 2020 to 1 Sep 2020.
- 21 Sep 2018 Planned primary completion date changed from 1 May 2019 to 1 Sep 2019.
- 19 Sep 2018 According to a Transgene media release, results evaluating primary endpoint are expected in the second half of 2019.